Navigation Links
Innovative Cancer Treatment Supported by NICE

LONDON, July 24, 2013 /PRNewswire/ --


The UK National Institute for Health and Clinical Excellence (NICE) has published guidance to support the routine use of SIRT (Selective Internal Radiation Therapy) for the treatment of patients with primary liver cancer.[1] This decision is good news for patients with the most-common form of primary liver cancer, called hepatocellular carcinoma or HCC, for whom few effective treatment options are available currently.

SIRT is used for the treatment of inoperable liver tumours and involves injecting millions of tiny radioactive microspheres into the liver via the hepatic artery (blood supply). Each microsphere is coated with a beta-emitting radioactive isotope called yttrium-90. The radiation delivers localised treatment to tumour cells whilst conserving normal liver cells. SIR-Spheres microspheres, a form of SIRT, were approved in Europe in 2002 and more than 35,000 treatments have been supplied worldwide. Over 500 patients have received this treatment in Britain. The NICE guidance, released on 24th July 2013, confirmed that the scientific evidence of the safety and efficacy of SIRT for patients with HCC is now considered adequate, which means that eligible National Health Service (NHS) patients are now likely to have improved access to this treatment.

Dr Harpreet Wasan, Consultant Oncologist at Hammersmith Hospital, Imperial College, said:

"SIRT is an innovative treatment for patients with inoperable primary liver tumours where few other effective treatment options are available.  It is excellent news that NICE has now published guidance supporting the latest evidence on SIRT in HCC and this should ensure suitable patients can access SIRT on the NHS.  I hope that, as a result, 'postcode prescribing' and treatment delays due to a lengthy funding application and approval process will no longer be a problem for treating eligible NHS patients with SIRT."

About Hepatocellular Carcinoma

HCC occurs most commonly in people whose livers have become severely damaged or cirrhotic, usually due to underlying liver conditions such as previous viral hepatitis infection or alcohol related liver damage. It is one of the ten most-common cancers in the world, with nearly 750,000 cases diagnosed annually, and is the third-leading cause of cancer deaths.[2] HCC occurs with greatest frequency in regions where hepatitis is most often diagnosed, such as in the Asia Pacific region and Southern Europe.

HCC can be cured only by surgery, either by resecting or ablating the diseased parts of the liver, or by transplantation with a liver from a donor. These interventions, however, are unsuitable for the great majority of patients, whose survival may range from a few months to two or more years depending largely on the state of their liver at the time of their diagnosis and the extent of tumour in the liver.

For Further Information:

SIR-Spheres microspheres are approved for use in Australia, the European Union (CE Mark), New Zealand, Switzerland, Turkey and several other countries for the treatment of unresectable liver tumours.

SIR-Spheres microspheres are also fully FDA PMA-approved and are indicated in the U.S. for the treatment of non-resectable metastatic liver tumours from primary colorectal cancer in combination with intra-hepatic artery chemotherapy using floxuridine.

®SIR-Spheres is a registered trademark of Sirtex SIR-Spheres Pty Ltd.


  1. National Institute for Health and Clinical Excellence. Selective internal radiation therapy for primary hepatocellular carcinoma (Interventional Procedure Guidance 460). London: NICE, July 2013.
  2. GLOBOCAN. Liver Cancer Incidence and Mortality Worldwide in 2008.


SOURCE Sirtex Medical Limited
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Innovative Krebsbehandlung wird von NICE unterstützt
2. UBM Canon and MD+DI Proudly Announce 27 Innovative Products as Winners of the 2013 Medical Design Excellence Awards
3. Andrews Institute offers innovative technology for spine surgery
4. Sirtex To Distribute Surefire Medicals Innovative Infusion System in Australia and Asia Pacific Markets
5. Remedy Informatics Awarded GSA Contract to Provide Innovative IT Solutions to Federal, State and Local Agencies
6. Romanoff Joins Innovative Statewide Program to Combat Abuse of Prescription Pain Medications
7. Neiman Center Issues Policy Brief Outlining Innovative Health Care Payment Models to Provide Cost-Effective Specialty Care for Patients
8. BlueBin Inc. Launches to Deliver Innovative Overhaul for Ailing Healthcare Supply Chain
9. VUCA Health Announces Rapid Adoption of its MedsOnCue Digital Patient Engagement Solution Supporting Health Literacy by Innovative Pharmacies across 19 States
10. TechAtlas Group Releases Innovative Chronic Kidney Disease Landscape Map
11. RAD Technology Medical Systems Delivers Innovative Time Saving Modular Construction At New Swedish Cancer Institute Facility
Post Your Comments:
(Date:11/25/2015)... , Nov. 25, 2015  Linden Care, LLC, ... optimizing treatment outcomes for patients suffering from chronic pain, ... for a Temporary Restraining Order (TRO) enjoining Express Scripts ... two companies. --> --> ... all of its legal options. --> ...
(Date:11/25/2015)... AVIV, Israel , November 25, 2015 ... (NASDAQ: KTOV ) (TASE: KTOV), a biopharmaceutical company ... simultaneous treatment of various clinical conditions, today announced the ... 3,158,900 American Depository Shares ( ADSs ), each representing ... purchase up to 3,158,900 ADSs. The ADSs and warrants ...
(Date:11/25/2015)... DUBLIN , Nov. 25, 2015 Endo International ... Rajiv De Silva , President and CEO, will discuss ... Healthcare Conference in New York on ... . Click on Investor Relations, and then the ... prior to the presentation,s start time to visit the site ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... Beddit® has launched a new Android app ... new app features a more intuitive SleepScore™ that rates sleep quality on a 100-point ... SleepScore is created by a proprietary algorithm. Beddit analyzes the data to provide an ...
(Date:11/25/2015)... ... November 25, 2015 , ... In an ongoing Clinical ... Center (RMC) in Chicago, IL, UV Angel is evaluating the efficacy of its product ... intensive care units (totaling 30 beds) from May 2014 through October 2015 at a ...
(Date:11/25/2015)... ... , ... Today, Mothers Against Drunk Driving (MADD) learned that the ... the first time since 2011. In 2014, there were 9,967 fatalities involving an alcohol ... National Highway Traffic Safety Administration (NHTSA), 32,675 people were killed in traffic crashes in ...
(Date:11/25/2015)... ... November 25, 2015 , ... In ... nation’s Periwinkle Pioneers, individuals and groups responsible for advancing care for pulmonary hypertension ... Pioneers, nominated by the public, will receive special recognition throughout 2016 as part ...
(Date:11/25/2015)... ... November 25, 2015 , ... Privately owned Contract Development ... expansion of its current state of the art research, development and manufacturing facility ... increase its manufacturing capacity as well as to support its clients’ growing research ...
Breaking Medicine News(10 mins):